8-K: Cencora Secures $4.5B for OneOncology Acquisition, Boosts Revolving Credit

Cencora, Inc. has finalized new credit facilities totaling $4.5 billion to fund its OneOncology acquisition and increased its revolving credit facility to $5.5 billion, replacing prior bridge financing.

Summary

• Cencora, Inc. entered into new credit agreements on January 12, 2026, to finance its previously announced acquisition of a majority stake in OneOncology.
• The company amended its existing Revolving Credit Facility, increasing aggregate commitments by $1.0 billion, bringing the total to $5.5 billion.
• A new Multi-Year Term Loan Facility of $1.5 billion was established, consisting of a $500 million Tranche One maturing in two years and a $1.0 billion Tranche Two maturing in three years from the funding date.
• A separate 364-Day Term Credit Facility of $3.0 billion was also secured, maturing 364 days from its funding date.
• Proceeds from both term loan facilities will be used to pay a portion of the OneOncology acquisition consideration, repay existing OneOncology debt, and cover associated fees and expenses.
• The new term loan facilities replace the previously disclosed $4.5 billion bridge financing commitments, which have been automatically reduced to zero.
• Interest rates for the term loans are based on Term SOFR or Daily Simple SOFR plus an applicable margin, ranging from 75 to 125 basis points over SOFR, or an alternate base rate plus 0 to 25 basis points, depending on Cencora's public debt ratings.
• Ticking fees on unused commitments for both term loan facilities will commence on April 1, 2026, ranging from 5.5 to 15 basis points based on public debt ratings.
• The 364-Day Term Credit Facility also includes a 0.10% duration fee on the commitment or outstanding loans as of May 29, 2026.
• Financial covenants include a leverage ratio not to exceed 4.00 to 1.00, with a temporary increase to 4.50 to 1.00 permitted during material acquisition periods.

Sentiment

Score: 7

Explanation: The sentiment is positive as Cencora successfully secured substantial financing for a major acquisition and enhanced its overall credit facilities. This indicates strong financial health and market confidence, despite the increased debt load. The replacement of bridge financing with committed term loans is a favorable development.

Positives

• Successfully secured significant financing totaling $4.5 billion for the OneOncology acquisition, demonstrating strong lender confidence.
• Increased the revolving credit facility by $1.0 billion to $5.5 billion, enhancing liquidity and financial flexibility for general corporate purposes.
• Replaced the bridge financing commitments with more structured term loan facilities, indicating a successful long-term financing strategy for the acquisition.
• The ability to prepay term loans at any time without premium or penalty (other than breakage costs) provides financial flexibility.

Negatives

• Incurrence of substantial new debt ($4.5 billion) will increase the company's overall leverage.
• Ticking fees will accrue on unused commitments for the term loan facilities starting April 1, 2026, adding to financing costs if funds are not drawn promptly.
• A duration fee of 0.10% is payable on the 364-Day Term Credit Facility, adding to the cost of this short-term financing.

Risks

• The funding of the term loans is subject to customary conditions, including the consummation of the OneOncology acquisition, meaning the financing could fall through if the acquisition does not close.
• Failure to comply with the financial leverage ratio covenant (not to exceed 4.00 to 1.00, or 4.50 to 1.00 during acquisition periods) could trigger an event of default.
• Changes in public debt ratings could affect the applicable margins for interest rates and ticking fees, potentially increasing borrowing costs.
• The company is exposed to interest rate fluctuations as the loans bear interest at rates tied to Term SOFR or Daily Simple SOFR.
• The 364-Day Term Credit Facility has a short maturity, requiring refinancing or repayment within a year of funding.

Future Outlook

The company's future outlook is tied to the successful consummation of the OneOncology acquisition, which these financing arrangements are designed to support. The new credit facilities provide the necessary capital structure for this strategic growth initiative, with repayment schedules aligned with the expected operational integration and financial performance post-acquisition.

Management Comments

• James F. Cleary, Executive Vice President and Chief Financial Officer, signed the report on behalf of Cencora, Inc., indicating management's formal approval and responsibility for the disclosed financial arrangements.

Industry Context

This financing activity positions Cencora to expand its presence in the oncology sector through the acquisition of OneOncology. The healthcare distribution industry often sees strategic acquisitions to consolidate market share, enhance service offerings, and achieve economies of scale. Securing substantial unsecured debt facilities at competitive rates, as indicated by the basis point spreads, suggests a favorable credit market environment and strong lender confidence in Cencora's financial health and strategic direction, even amidst a large acquisition. The replacement of bridge financing with longer-term facilities is a common and prudent step in large M&A transactions, reflecting a move towards a more stable capital structure.

Comparison to Industry Standards

• The leverage ratio covenant of 4.00:1.00 (with a temporary increase to 4.50:1.00 for material acquisitions) is within typical ranges for investment-grade companies undertaking strategic acquisitions in the healthcare sector, balancing growth ambitions with financial prudence.
• The interest rate margins (75-125 bps over SOFR for multi-year, 87.5-112.5 bps for 364-day) are competitive for senior unsecured term loans for a company with Cencora's public debt ratings (A/A2/A to BBB/Baa2/BBB), reflecting its creditworthiness in the market.
• The replacement of bridge financing with committed term facilities is a standard practice in large acquisitions, indicating successful syndication and a preference for more stable, long-term capital over short-term, higher-cost bridge loans.

Corporate Governance

Related Party Transactions

• Certain lenders under the Revolving Credit Facility, Term Credit Agreement, and 364-Day Term Credit Agreement, and their affiliates, have provided and may continue to provide investment banking, commercial banking, derivative transactions, and financial advisory services to Cencora and its affiliates in the ordinary course of business, for which they receive fees and commissions.
• Citigroup Global Markets Inc., an affiliate of Citibank, N.A., is serving as lead financial advisor for the acquisition.
• J.P. Morgan Securities LLC, an affiliate of JPMorgan Chase Bank, N.A., is serving as financial advisor for the acquisition.
• Several lenders or their affiliates (BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, BNP Paribas Securities Corp., Société Générale Corporate & Investment Banking) have served as joint book-running managers or underwriters for past senior note offerings and may do so in the future.
• Certain lenders also serve various roles in a $1.5 billion receivables securitization facility involving Cencora's subsidiaries.

Stakeholder Impact

• **Shareholders**: The successful financing of the OneOncology acquisition could be viewed positively as it enables strategic growth, but the increased debt load will impact financial ratios and potentially future earnings per share due to interest expenses.
• **Creditors**: The new debt facilities increase Cencora's overall indebtedness, which could affect credit risk profiles. However, the replacement of bridge financing with committed term loans provides more certainty.
• **Employees**: The acquisition of OneOncology implies potential integration efforts and changes, which could impact employees of both Cencora and OneOncology.
• **Customers/Suppliers**: The acquisition aims to expand Cencora's offerings in oncology, potentially leading to enhanced services or broader reach for customers and new opportunities or changes for suppliers.

Next Steps

• Consummation of the proposed acquisition of the majority of outstanding equity interests in OneOncology.
• Repayment of existing debt of OneOncology using proceeds from the new term loans.
• Payment of fees and expenses incurred in connection with the acquisition and financing.
• Ongoing compliance with financial covenants, including the leverage ratio, under the new credit agreements.
• Accrual and payment of ticking fees on unused commitments starting April 1, 2026.
• Payment of the duration fee for the 364-Day Term Credit Facility on the first Business Day after May 29, 2026.

Key Dates

Recommendation

The filing details the successful securing of significant financing for a major acquisition and an increase in the revolving credit facility. This is a positive step for Cencora's strategic growth, demonstrating strong market confidence in its ability to execute the OneOncology acquisition. However, the filing primarily focuses on the financing structure rather than the intrinsic value or strategic merits of the acquisition itself. While the financing is well-structured and replaces bridge commitments, the increased debt load and associated costs warrant a neutral 'hold' stance until further details on the acquisition's expected financial impact and integration plan are available to fully assess the long-term value creation for shareholders.

Keywords

Cencora, OneOncology acquisition, Term Loan Facility, Revolving Credit Facility, Debt Financing, SEC Filing, Corporate Finance, Healthcare Distribution, Credit Agreement, Leverage Ratio